[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Induced Pluripotent Stem Cells (iPSCs) Market 2022-2028

September 2022 | 73 pages | ID: GB4FBEBA8DC0EN
Gen Consulting Company

US$ 2,600.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global induced pluripotent stem cells market size is projected to grow by USD 2 billion from 2022 to 2028, registering a CAGR of 8.6 percent, according to a new report by Gen Consulting Company.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global induced pluripotent stem cells market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the induced pluripotent stem cells industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the function, reprogramming method, method, application, and region. The global market for induced pluripotent stem cells can be segmented by function: cell analysis, cell culture, cell differentiation, cellular and molecular bioengineering, cellular reprogramming. In 2021, the cell differentiation segment made up the largest share of revenue generated by the induced pluripotent stem cells market. Induced pluripotent stem cells market is further segmented by reprogramming method: integrated, non-integrated. The non-integrated segment was the largest contributor to the global induced pluripotent stem cells market in 2021. Based on method, the induced pluripotent stem cells market is segmented into: DNA-based, protein-based, RNA-based, small molecule-based. The DNA-based segment is estimated to account for the largest share of the global induced pluripotent stem cells market. On the basis of application, the induced pluripotent stem cells market also can be divided into: academic research, drug development, regenerative medicine. The drug development segment held the largest share of the global induced pluripotent stem cells market in 2021 and is anticipated to hold its share during the forecast period. Induced pluripotent stem cells market by region is categorized into: Asia Pacific, Europe, USA, Rest of the World (RoW).

By function:
  • cell analysis
  • cell culture
  • cell differentiation
  • cellular and molecular bioengineering
  • cellular reprogramming
By reprogramming method:
  • integrated
  • non-integrated
By method:
  • DNA-based
  • protein-based
  • RNA-based
  • small molecule-based
By application:
  • academic research
  • drug development
  • regenerative medicine
By region:
  • Asia Pacific
  • Europe
  • USA
  • Rest of the World (RoW)
The report explores the recent developments and profiles of key vendors in the Global Induced Pluripotent Stem Cells Market, including Bio-Techne Corporation, BlueRock Therapeutics LP, Bristol Myers Squibb (BMS), Cell Signaling Technology, Inc., Corning Incorporated, FUJIFILM Cellular Dynamics, Inc., InvivoGen Limited, Lonza Group AG, Merck KGaA, Promega Corporation, Qiagen N.V., STEMCELL Technologies Inc., Thermo Fisher Scientific Inc., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
  • To analyze and forecast the market size of the global induced pluripotent stem cells market.
  • To classify and forecast the global induced pluripotent stem cells market based on function, reprogramming method, method, application, region.
  • To identify drivers and challenges for the global induced pluripotent stem cells market.
  • To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global induced pluripotent stem cells market.
  • To identify and analyze the profile of leading players operating in the global induced pluripotent stem cells market.
Why Choose This Report
  • Gain a reliable outlook of the global induced pluripotent stem cells market forecasts from 2022 to 2028 across scenarios.
  • Identify growth segments for investment.
  • Stay ahead of competitors through company profiles and market data.
  • The market estimate for ease of analysis across scenarios in Excel format.
  • Strategy consulting and research support for three months.
  • Print authentication provided for the single-user license.
PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY FUNCTION

Cell analysis
Cell culture
Cell differentiation
Cellular and molecular bioengineering
Cellular reprogramming

PART 6. MARKET BREAKDOWN BY REPROGRAMMING METHOD

Integrated
Non-integrated

PART 7. MARKET BREAKDOWN BY METHOD

DNA-based
Protein-based
RNA-based
Small molecule-based

PART 8. MARKET BREAKDOWN BY APPLICATION

Academic research
Drug development
Regenerative medicine

PART 9. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
USA
Rest of the World (RoW)

PART 10. KEY COMPANIES

Bio-Techne Corporation
BlueRock Therapeutics LP
Bristol Myers Squibb (BMS)
Cell Signaling Technology, Inc.
Corning Incorporated
FUJIFILM Cellular Dynamics, Inc.
InvivoGen Limited
Lonza Group AG
Merck KGaA
Promega Corporation
Qiagen N.V.
STEMCELL Technologies Inc.
Thermo Fisher Scientific Inc.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER


More Publications